Free Delivery Over $100
|
|
|||
|
||||
OverviewProtein Design and Structure, Volume 130 in the Advances in Protein Chemistry and Structural Biology series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors. Full Product DetailsAuthor: Rossen Donev (Head of Research, MicroPharm Limited, UK)Publisher: Elsevier Science & Technology Imprint: Academic Press Inc Weight: 0.840kg ISBN: 9780323992299ISBN 10: 0323992293 Pages: 432 Publication Date: 27 April 2022 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of Contents1. Algorithms for protein design Sekhar Talluri 2. Computational prediction of protein functional sites—Applications in biotechnology and biomedicine Florencio Pazos 3. Structure and chemistry of enzymatic active sites that play a role in the switch and conformation mechanism Chandrabose Selvaraj, Ondipilliraja Rudhra, Abdulaziz S. Alothaim, Mustfa Alkhanani, and Sanjeev Kumar Singh 4. Accelerating therapeutic protein design Mohammad ElGamacy 5. Aromatic interactions directing peptide nano-assembly Sajitha Sasidharan and Vibin Ramakrishnan 6. Understanding binding affinity and specificity of modular protein domains: A focus in ligand design for the polyproline-binding families Jose C. Martinez, Francisco Castillo, Javier Ruiz-Sanz, Javier Murciano-Calles, Ana Camara-Artigas, and Irene Luque 7. The structural basis of histone modifying enzyme specificity and promiscuity: Implications for metabolic regulation and drug design Tim J. Kamerzell, Brittney Mikell, Lei Chen, Harold Elias, Buddhadeb Dawn, Calum MacRae, and C. Russell Middaugh 8. Designing synthetic transcription factors: A structural perspective Aparna Boral, Madhurima Khamaru, and Devrani Mitra 9. Recent advances in structural studies of 14-3-3 protein complexes Nikolai N. Sluchanko 10. Immunosafe(r)-by-design nanoparticles: Molecular targets and cell signaling pathways in a next-generation model proxy for humans Annalisa Pinsino and Maria Di Bernardo 11. Mutations in G6PC2 gene with increased risk for development of type 2 diabetes: Understanding via computational approach S. Udhaya Kumar, Balu Kamaraj, Rinku Polachirakkal Varghese, V. Anu Preethi, R. Bithia, and C. George Priya Doss 12. Computational structural assessment of BReast CAncer type 1 susceptibility protein (BRCA1) and BRCA1-Associated Ring Domain protein 1 (BARD1) mutations on the protein-protein interface D. Thirumal Kumar, S. Udhaya Kumar, Nikita Jain, Baviri Sowmya, Kamakshi Balsekar, R. Siva, Balu Kamaraj, Mariem Sidenna, C. George Priya Doss, and Hatem Zayed 13. Evolutionary aspect of Miltefosine transporter proteins in Leishmania major Ritika Kabra and Shailza SinghReviewsAuthor InformationRossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications. Tab Content 6Author Website:Countries AvailableAll regions |
||||
